Literature DB >> 27354265

Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Phyllis A Gimotty1, Ronald Shore2, Nancy L Lozon2, Jeanne Whitlock2, Sidan He3, Fawn D Vigneau2, Lois Dickie4, David E Elder5, Xiaowei Xu5, Ann G Schwartz2, DuPont Guerry6.   

Abstract

Melanoma-related deaths and metastases among patients with thin (≤1 mm) and ultrathin (≤0.25 mm) melanomas have been reported. These observations might reflect adverse biology and/or errors in administrative data. Cumulative melanoma-related death rates for thickness groups of patients with thin melanomas were compared among five cohorts including the Surveillance, Epidemiology, and End Results (SEER) registry. Thickness in one SEER region was reexamined in pathology reports. The 5-year cumulative melanoma-related death rate of patients with ultrathin melanomas was higher in SEER (2.8%) compared with other registries (0.6-0.9%). The rates across the 16 SEER regions were 0.25% to 8.4%. In SEER, 21% of thin melanomas were ultrathin; in other registries, they comprised 5.8-15%. A reexamination of thickness in one SEER site revealed that 114 of 447 ultrathin melanomas had errors; after correction, only 17 of the 114 remained ultrathin. The majority of errors were related to decimal point placement. The 86 thin melanomas reclassified to >1.00 mm included 96% of the original ultrathin-associated deaths and 100% of the original positive lymph nodes. Significant miscoding of thickness that is concentrated in ultrathin lesions is present in SEER and results in mischaracterization of patient outcomes. When using administrative data, validation of results can identify critical data issues.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27354265      PMCID: PMC5077675          DOI: 10.1016/j.jid.2016.05.121

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.

Authors:  Maxine Sun; Quoc-Dien Trinh
Journal:  BJU Int       Date:  2015-08-16       Impact factor: 5.588

Review 2.  Prognostication in thin cutaneous melanomas.

Authors:  Phyllis A Gimotty; DuPont Guerry
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

3.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia.

Authors:  David C Whiteman; Peter D Baade; Catherine M Olsen
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

4.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

6.  Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit.

Authors:  J Gregory McKinnon; Xue Qin Yu; William H McCarthy; John F Thompson
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

7.  Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register.

Authors:  J Lyth; J Hansson; C Ingvar; E Månsson-Brahme; P Naredi; U Stierner; G Wagenius; C Lindholm
Journal:  Br J Dermatol       Date:  2013-01-18       Impact factor: 9.302

8.  Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.

Authors:  Sanjay P Bagaria; Partha S Ray; Richard W Joseph; Michael G Heckman; Bhupendra Rawal; Richard J Gray; Barbara Pockaj; Nabil Wasif
Journal:  Cancer       Date:  2013-02-13       Impact factor: 6.860

9.  Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.

Authors:  Ulrike Leiter; Petra G Buettner; Thomas K Eigentler; Claus Garbe
Journal:  J Clin Oncol       Date:  2004-08-09       Impact factor: 44.544

10.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD).

Authors:  Gary S Collins; Johannes B Reitsma; Douglas G Altman; Karel G M Moons
Journal:  Ann Intern Med       Date:  2015-05-19       Impact factor: 25.391

View more
  5 in total

1.  Mitotic rate is associated with positive lymph nodes in patients with thin melanomas.

Authors:  Lee Wheless; Chelsea A Isom; Mary A Hooks; Rondi M Kauffmann
Journal:  J Am Acad Dermatol       Date:  2017-12-01       Impact factor: 11.527

2.  Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment.

Authors:  Makenzie L Hawkins; Matthew J Rioth; Megan M Eguchi; Myles Cockburn
Journal:  J Am Acad Dermatol       Date:  2019-01-14       Impact factor: 15.487

3.  Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions.

Authors:  Zhichao Wang; Haizhou Li; Xinyang Liu; Jinhong Bae; Xin Huang; Yashan Gao; Xiangwen Xu; Jihan Guo; Lin Lu; Tao Zan; Qingfeng Li
Journal:  Oncotarget       Date:  2017-10-24

4.  Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004-2016.

Authors:  Qiuying Ma; Huinan Suo; Li Zhu; Yue Qian; Xiaoyan Sun; Jun Xie; Qianru Li; Yangxue Fu; Jun Li; Juan Tao
Journal:  Cancer Med       Date:  2020-05-05       Impact factor: 4.452

5.  Prognostic factors for postoperative survival in melanoma patients with bone metastasis.

Authors:  Yucheng Wang; Shihong Ren; Xiaokang Gong; Jiacheng Wang; Ning Zhu; Danyang Cai; Jianwei Ruan
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.